Article
Vemurafenib in Chinese patients with BRAFV600 mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study.
BMC cancer - 3 May 2018
Si Lu, Zhang Xiaoshi, Xu Zhen, Jiang Qiudi, Bu Lilian, Wang Xuan, Mao Lili, Zhang Weijiang, Richie Nicole, Guo Jun
Abstract excerpt
BACKGROUND: Melanoma is a rare, deadly disease without effective treatment options in China. Vemurafenib is a selective inhibitor of oncogenic BRAFV600 kinase approved in more than 90 countries, based on results obtained primarily in Caucasian patients. Limited data are available regarding the efficacy and safety of vemurafenib in Asian patients. METHODS: This phase I study investigated the pharmacokinetics,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.